Autem Therapeutics Overview

  • Year Founded
  • 2017

Year Founded

  • Status
  • Private

  • Employees
  • 15

Employees

  • Latest Deal Type
  • Mezzanine

  • Latest Deal Amount
  • $1.5M

  • Investors
  • 3

Autem Therapeutics General Information

Description

Developer of an electromagnetic frequency non-thermal therapy treatment designed for cancer patients. The company's therapy treatment delivers personalized, amplitude-modulated electromagnetic frequencies to patients systemically, targeting Hepatocellular Carcinoma and other solid tumor cancers, enabling patients with early and advanced-stage cancer to avail therapy proven by initial clinical studies to enhance the quality of life and extend survival.

Contact Information

Formerly Known As
Autem Medical
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 35 South Main Street
  • Suite 208
  • Hanover, NH 03755
  • United States
+1 (215)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Therapeutic Devices
Corporate Office
  • 35 South Main Street
  • Suite 208
  • Hanover, NH 03755
  • United States
+1 (215)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Autem Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Mezzanine 04-Apr-2024 $1.5M Completed Generating Revenue
3. Later Stage VC (Series A1) 07-Jun-2022 Completed Generating Revenue
2. Seed Round 15-Dec-2021 $2M $2M Completed Startup
1. Seed Round Completed Startup
To view Autem Therapeutics’s complete valuation and funding history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Autem Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Autem Therapeutics Investors (3)

Investor Name Investor Type Holding Investor Since Participating Rounds
Venturance Alternative Assets Asset Manager Minority
Zentynel Frontier Investments Venture Capital Minority
Biominas Brasil Accelerator/Incubator
To view Autem Therapeutics’s complete investors history, request access »

Autem Therapeutics FAQs

  • When was Autem Therapeutics founded?

    Autem Therapeutics was founded in 2017.

  • Where is Autem Therapeutics headquartered?

    Autem Therapeutics is headquartered in Hanover, NH.

  • What is the size of Autem Therapeutics?

    Autem Therapeutics has 15 total employees.

  • What industry is Autem Therapeutics in?

    Autem Therapeutics’s primary industry is Drug Discovery.

  • Is Autem Therapeutics a private or public company?

    Autem Therapeutics is a Private company.

  • What is Autem Therapeutics’s current revenue?

    The current revenue for Autem Therapeutics is .

  • How much funding has Autem Therapeutics raised over time?

    Autem Therapeutics has raised $13.5M.

  • Who are Autem Therapeutics’s investors?

    Venturance Alternative Assets, Zentynel Frontier Investments, and Biominas Brasil have invested in Autem Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process